Общие принципы и основные рекомендации по ведению и лечению пациентов с подагрой по материалам обновленных европейских рекомендаций


Цитировать

Полный текст

Аннотация

В 2016 г. опубликованы обновленные европейские общие принципы и основные рекомендации по ведению пациентов с подагрой. Акцент делается на фармакологические/нефармакологические методы лечения и на уратснижающую терапию у пациентов с нарушением функции почек. Впервые в России наряду с аллопуринолом рекомендуется препарат с уратснижающим эффектом - фебуксостат. Цель данного обзора - донести до врачей возможность обязательного достижения целевого уровня мочевой кислоты при лечении подагры с гиперурикемией.

Об авторах

Владимир Викторович Цурко

ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова», ФГБОУ ВО «РНИМУ им. Н.И.Пирогова»

д-р мед. наук, проф. каф. гематологии и гериатрии ИПО, проф. каф. факультетской терапии лечебного фак-та 117997, Россия, Москва, ул. Островитянова, д. 1

Маргарита Александровна Громова

ФГБОУ ВО «РНИМУ им. Н.И.Пирогова»

Email: margarita-gromov@mail.ru
канд. мед. наук, ассистент каф. факультетской терапии лечебного фак-та 117997, Россия, Москва, ул. Островитянова, д. 1

Список литературы

  1. Hootman J.M, Helmick C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthr Rheum 2006; 54: 226-9.
  2. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры - научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004; 1: 5-7.
  3. Geiderman J.M. An elderly woman with a warm, painful finger. West J Med 2000; 172 (1): 51-2.
  4. Richette P, Doherty M, Pascual E et al. Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2016; Jul 25. PII: annrheumdis-2016-209707. doi: 10.1136/annrheumdis-2016-209707
  5. Simkin P.A, Campbell P.M, Larson E.B. Brief report: Gout in Heberden’s nodes. Arthr Rheum 1983; 26: 97-104. doi: 10.1016/j.berh.2015.04.024
  6. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013; 72: 826-30.
  7. Choi J.W, Ford E.S, Gao X. et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59: 109-16.
  8. Zhang Y, Neogi T, Chen C. et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum 2012; 64: 4004-11.
  9. Dalbeth N, Ames R, Gamble G.D. et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis 2012; 71: 929-34.
  10. Chen J.H, Wen C.P, Wu S.B. et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis 2015; 74: 2034-42.
  11. Terkeltaub R.A, Furst D.E, Bennett K. et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62: 1060-8.
  12. Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig 2014; 34: 845-55.
  13. Terkeltaub R.A, Furst D.E, Digiacinto J.L. et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011; 63: 2226-37.
  14. Van Durme C.M, Wechalekar M.D., Buchbinder R. et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; 9: CD010120.
  15. Rainer T.H, Cheng C.H, Janssens H.J. et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 2016; 164: 464-71.
  16. Janssens H.J, Janssen M, van de Lisdonk E.H. et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet 2008; 371: 1854-60.
  17. Wechalekar M.D, Vinik O, Schlesinger N. et al. Intra-articularglucocorticoids for acute gout. Cochrane Database Syst Rev 2013; 4: CD009920.
  18. Schlesinger N, Alten R.E, Bardin T. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71: 1839-48.
  19. Ghosh P, Cho M, Rawat G. et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013; 65: 1381-4.
  20. Finkelstein Y, Aks S.E, Hutson J.R. et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 2010; 48: 407-14.
  21. Becker M.A, MacDonald P.A, Hunt B.J. et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides. Nucleic Acids 2008; 27: 585-91.
  22. Wortmann R.L, Macdonald P.A, Hunt B. et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010; 32: 2386-97.
  23. Halevy S, Ghislain P.D, Mockenhaupt M. et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
  24. Weisskopf M.G, O’Reilly E, Chen H. et al. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 2007; 166: 561-7.
  25. Kim T.S, Pae C.U, Yoon S.J. et al. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatric Psychiatry 2006; 21: 344-8.
  26. Abraham A, Drory V.E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 2014; 261: 1133-8.
  27. Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine 2015; 82: 141-3.
  28. Noman A, Ang D.S, Ogston S. et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375: 2161-7.
  29. Bardin T, Chales G, Pascart T. et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 2016; 83: 314-7.
  30. Kydd A.S, Seth R, Buchbinder R. et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev 2014; 11: CD010457.
  31. Hira D, Chisaki Y., Noda S. et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 2015; 96: 90-8.
  32. Schumacher H.R Jr, Becker M.A, Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-8.
  33. Becker M.A, Schumacher H.R.Jr, Wortmann R.L et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-61.
  34. Becker M.A, Schumacher H.R, Espinoza L.R et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12: R63.
  35. Abeles A.M. Febuxostat hypersensitivity. J Rheumatol 2012; 39: 659.
  36. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011; 38: 1957-9.
  37. Givertz M.M, Anstrom K.J, Redfield M.M. et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation 2015; 131: 1763-71.
  38. Choi H.K, Soriano L.C, Zhang Y. et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344: d8190.
  39. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fen of ibrate: a systematic review and meta-analysis of randomized placebo controlled trials. Pharmacol Res 2015; 102: 63-70.
  40. Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol 2012; 157: 255-7.
  41. Rothenbacher D, Primatesta P, Ferreira A.et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 2011; 50: 973-81.
  42. Dalbeth N, Chen P., White M. et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis 2014; 73: 797-802.
  43. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol 2011; 23: 156-60.
  44. Luk A.J, Simkin P.A. Epidemiology of Hyperuricemia and Gout. Am J Manag Care 2005; 11: 435-42.
  45. Roddy E, Choi H.K. Epidemiology of gout. Rheum Dis Clin North Am 2014; 40: 155-75.
  46. Атаханова Л.Э., Цурко В.В., Булеева И.М. и др. Подагра: от этиологии и патогенеза к диагностике и рациональной терапии. Современная ревматология. 2007; 1: 13-8.
  47. Kuo C.F., Grainge M.J, Mallen C. et al. Eligibility for and prescription of urate-lowering treatmentinpat in patients with incident gout in England. JAMA 2015; 312: 2684-6.
  48. Цурко В.В., Елисеева М.Е., Воробьев П.А. Особенности течения подагры в пожилом возрасте. Терапевт. арх. 2014; 5 (86): 50-5.
  49. Воробьев П.А., Цурко В.В., Елисеева М.Е. Подагра в гериатрической практике. Методические рекомендации. Часть I. Клин. геронтология. 2016; 3-4 (22): 3-9.
  50. Liu S.C, Xia L, Zhang J. et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS ONE 2015; 10: e0134088.
  51. Clarson L.E, Hider S.L, Belcher J. et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis 2015; 74: 642-7.
  52. Choi H.K, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
  53. Juraschek S.P, Kovell L.C, Miller E.R. et al. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum 2013; 42 (6): 551-61.
  54. Кашкадаева А.В., Аверинова С.Г., Алехин А.П. и др. Диагностика факторов риска почечной недостаточности на базе концентрационно-скоростного подхода к анализу результатов комплексной реносцинтиграфии в онкологической практике. Рос. электронный журн. лучевой диагностики. 2013; 3 (2): 47-62. www.rejr.ru
  55. Sayapina M.S, Averinova S.G, Zacharova T.V. et al. Complex Monitoring of Biochemical and Radionuclide Parameters in Patients with Metastatic Renal Cell Carcinoma during Immunotherapy. Int J Nephrology 2017. doi: 10.1155/2017/8549502
  56. Саяпина М.С., Аверинова С.Г., Захарова Т.В. и др. Биохимический и радионуклидный мониторинг функции единственной почки у больных метастатическим почечно-клеточным раком на фоне иммунотерапии. Экспериментальная и клин. урология. 2017; 3: 118-25.

© ООО "Консилиум Медикум", 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах